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1 |  INTRODUCTION
Major depression is highly prevalent, debilitating and eco-
nomically burdensome psychiatric disorder. Pharmacotherapy 
with conventional antidepressants (eg selective serotonin 
reuptake inhibitors) is the most commonly used treatment 
option, but a large proportion of patients do not receive suf-
ficient benefit and remain treatment- resistant. The discovery 
of the rapid- acting antidepressant effects of the N- methyl- 
D- aspartate receptor (NMDAR) antagonist ketamine, a 
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Abstract
Increased glutamatergic neurotransmission and synaptic plasticity in the prefron-
tal cortex have been associated with the rapid antidepressant effects of ketamine. 
Activation of BDNF (brain- derived neurotrophic factor) receptor TrkB is considered 
a key molecular event for antidepressant- induced functional and structural synaptic 
plasticity. Several mechanisms have been proposed to underlie ketamine's effects on 
TrkB, but much remains unclear. Notably, preliminary studies suggest that besides 
ketamine, nitrous oxide (N2O) can rapidly alleviate depressive symptoms. We have 
shown nitrous oxide to evoke TrkB signalling preferentially after the acute pharma-
cological effects have dissipated (ie after receptor disengagement), when slow delta 
frequency electroencephalogram (EEG) activity is up- regulated. Our findings also 
demonstrate that various anaesthetics and sedatives activate TrkB signalling, further 
highlighting the complex mechanisms underlying TrkB activation. We hypothesize 
that rapid- acting antidepressants share the ability to regulate TrkB signalling during 
homeostatically evoked slow- wave activity and that this mechanism is important for 
sustained antidepressant effects. Our observations urge the examination of rapid and 
sustained antidepressant effects beyond conventional receptor pharmacology by fo-
cusing on brain physiology and temporally distributed signalling patterns spanning 
both wake and sleep. Potential implications of this approach for the improvement of 
current therapies and discovery of novel antidepressants are discussed.
K E Y W O R D S
electroencephalogram, energy metabolism, protein phosphorylation, rapid- acting antidepressant, 
sleep
dissociative anaesthetic drug, has brought renewed interest 
towards the research and development of antidepressants 
with a more rapid onset of action.1 The antidepressant ef-
fects of a single intravenous dose of subanaesthetic ketamine 
(0.1- 0.5  mg/kg, iv) are typically observed already within a 
few hours, although in most cases the effects become more 
prominent the following day.1- 4 However, the antidepressant 
effects of ketamine are transient and commonly sustained for 
only up to a week.5
Two decades of intensive research have led to many im-
portant discoveries about ketamine's antidepressant effects, 
yet the precise mechanism through which ketamine exerts 
its therapeutic effects remains unclear.4,6- 9 Subanaesthetic 
dose ketamine is thought to preferentially block of NMDARs 
expressed in inhibitory gamma- aminobutyric acid (GABA)- 
ergic interneurons.9 By reducing GABAergic tone, ket-
amine disinhibits the activity of glutamatergic pyramidal 
neurons, leading to enhanced glutamate release and burst-
ing. Increased glutamate activates post- synaptic α- amino- 
3- hydroxy- 5- methyl- 4- isoxazolepropionic acid receptors 
(AMPARs). These, and other mechanisms induced by ket-
amine, have been proposed to ultimately converge on in-
creased translation and release of brain- derived neurotrophic 
factor (BDNF), a key regulator of antidepressant actions4 
(Figure 1). BDNF and its receptor TrkB can regulate a myr-
iad of downstream signalling effectors leading to increased 
transcription, translation and trafficking of the components 
involved in synaptic plasticity. Recent studies have also pro-
posed that ketamine's antidepressant effects are mediated by 
its 2R,6R- hydroxynorketamine (HNK) metabolite,10 or that 
ketamine and HNK directly bind to TrkB receptors and facil-
itate their responsiveness to BDNF.11 Despite these findings, 
the dose and time- dependent effects of ketamine, or its me-
tabolites, on TrkB phosphorylation and signalling in the adult 
brain have been only scarcely studied.
Ketamine has relatively short half- life, and its antide-
pressant effects greatly outlast acute receptor- level effects 
triggered by the drug.9 Early clinical evidence indicates 
that nitrous oxide, a gaseous NMDAR antagonist that is 
eliminated (unchanged) even more rapidly, may also pro-
duce rapid and sustained antidepressant effects.12 The 
emergence of these rapid yet sustained effects is diffi-
cult to explain through principles of conventional recep-
tor pharmacology, which have been previously applied to 
the study of monoaminergic drugs. Moreover, some non- 
pharmacological treatments capable of inducing prom-
inent changes on glutamatergic system and global brain 
activity, most notably sleep deprivation and treatments 
inducing transient seizures (eg electroconvulsive therapy 
(ECT)), also possess rapid antidepressant potential.6,13,14 
Therefore, the antidepressant effects of ketamine, and other 
rapid- acting treatments, may be connected to shared mo-
lecular and physiological adaptions in brain networks that 
underlie the pathophysiology of depression. However, the 
effects of nitrous oxide, sleep deprivation and seizures on 
TrkB signalling have not been systematically investigated. 
In this minireview, we overview our recent findings and ef-
forts in this context, with an emphasis on the shared ability 
of rapid- acting antidepressants to increase neuronal exci-
tation and synaptic potentiation in the cortex during their 
acute pharmacological or physiological effects. Moreover, 
we discuss the hypothesis that concomitant brain activity 
and associated molecular changes, which may emerge only 
after the excitatory effects of said treatments have waned 
off, may be important in understanding rapid antidepres-
sant action. Finally, we summarize our observations related 
to the activation of TrkB signalling by nitrous oxide and 
seizures, which takes place preferentially after their acute 
effects on cortical excitation have subsided, giving way to a 
brain state dominated by slow delta frequency EEG activity 
resembling deep slow- wave sleep.13 Subanaesthetic dose 
F I G U R E  1  Some of the proposed mechanisms underlying 
subanaesthetic ketamine's effects on TrkB signalling. A, Ketamine 
blocks NMDARs on inhibitory GABAergic interneurons resulting 
in the disinhibition of glutamate release and the activation of post- 
synaptic AMPARs, which evoke BDNF synthesis and trafficking. 
Activation of TrkB leads to changes in downstream signalling 
including activation of p44/42- MAPK and mTor- p70S6k, and 
inhibition of GSK3β, which ultimately alter gene transcription 
(eg Bdnf and synaptic proteins). B, Ketamine metabolite 2R,6R- 
hydroxynorketamine (HNK) has been shown to regulate glutamate 
release in an NMDAR- independent manner. C, Blockade of post- 
synaptic NMDARs have been proposed to induce local translation of 
BDNF
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ketamine also leads to the increases in slow- wave EEG ac-
tivity after its acute excitatory effects have dissipated. We 
argue that understanding the complex neuronal responses 
to treatments like subanaesthetic dose ketamine— and their 
association with the neurobiology of sleep— could be an 
important piece of the puzzle towards a more compre-
hensive picture of fast- acting antidepressants and a start-
ing point for the development of novel treatments against 
major depression.
2 |  SHARED NEUROBIOLOGICAL 
BASIS FOR RAPID- ACTING 
ANTIDEPRESSANTS
2.1 | Cortical excitation
The molecular, functional and structural changes asso-
ciated with subanaesthetic ketamine and other putative 
rapid- acting antidepressant treatments, such as nitrous 
oxide, sleep deprivation and electroconvulsive therapy, are 
strikingly similar despite clear physiological differences. 
For ketamine, the proposed mechanisms— more or less— 
converge on increased cortical excitation, often accompa-
nied by increases in brain energy metabolism (reviewed 
in4,6). The induction of neuronal activity by subanaesthetic 
ketamine is thought to be mediated, at least in part, through 
the disinhibition of glutamate release.9 By preferentially 
blocking NMDARs on inhibitory interneurons, ketamine 
may reduce the inhibition of excitatory pyramidal neurons 
resulting in increased glutamate release and bursting.15,16 
Anaesthetic doses, however, lead to more general inhibi-
tory effects, presumably through widespread blockade of 
NMDARs also on principal neurons. While many studies 
have investigated the dose- dependent effects of ketamine, 
there is no clear clinical evidence for the antidepressant ef-
fects of ketamine being limited to a specific subanaesthetic 
dose.4
The subanaesthetic ketamine- induced glutamate release 
activates AMPARs and triggers post- synaptic signalling 
mechanisms, which have been proposed to include the 
rapid translation and release of BDNF and the activation 
of its receptor TrkB (Figure 1). Through the regulation of 
downstream mechanisms such as mitogen- activated protein 
kinase (MAPK) and the activation of the mammalian target 
of rapamycin (mTOR) and its effector ribosomal protein 
S6 kinase beta- 1 (also known as p70S6K) and the inhibi-
tion of glycogen synthase kinase 3β (GSK3β), ketamine is 
thought to modulate the synthesis and trafficking of neuro-
trophic and synaptic proteins allowing anabolic effects on 
synaptic structure, function and number— at least in ani-
mal models of depression. Within hours of administration, 
ketamine appears to rapidly alter cortical neuronal activity 
and connectivity in both human beings and rodents,6,17- 19 
which may be a consequence of synaptic potentiation. On a 
longer timescale, ketamine increases the formation of den-
dritic spines, especially in the medial prefrontal cortex of 
chronically stressed rodents, which has been suggested to 
be important for the sustained antidepressant effects.17,20 
These findings of restored connectivity and increased 
synaptic strength in animal models are mirrored by clin-
ical observations in depressed patients receiving ketamine 
therapy.6,19,21- 23
Electroconvulsive therapy and sleep deprivation (ie 
prolonged waking)— non- pharmacological treatments pos-
sessing rapid antidepressant potential— share the property 
of subanaesthetic ketamine to induce global cortical exci-
tation, as well as many of the other functional and molecu-
lar features associated with ketamine.6 In ECT, an induced 
alternating current forces groups of cortical neurons to fire 
simultaneously, ultimately resulting in the propagation 
and generalization of epileptiform activity. Seizures can 
also be provoked by pharmacological convulsants, such as 
flurothyl,24 which either suppress inhibitory or activate ex-
citatory receptors to elicit similar outcomes. The neuronal 
activity inducing effects and associated molecular alter-
ations of convulsive therapies have been studied thoroughly 
in animals.25,26 Most notably, flurothyl has been effectively 
used as treatments of depression in the past. Sleep depri-
vation also increases cortical excitation and extracellular 
glutamate levels. Notably, other experimental treatments 
with rapid and long- lasting antidepressant potential, such 
as scopolamine and psychedelic drugs, may also acutely 
increase cortical excitatory activity and glutamate release.6 
The effects of classic psychedelics such as psilocybin 
may, however, be more specific as their primary targets, 
the 5HT2A receptors, are enriched in evolutionarily recent 
brain areas implicated in depression. Notably, we have re-
cently shown that nitrous oxide also up- regulates markers 
of cortical excitability and induces MAPK signalling in the 
cortex of rodents.13 Nitrous oxide has shown initial prom-
ise in treating depression, but larger clinical trials are still 
underway.12
The aforementioned studies establish a perspective sug-
gesting that a shared feature for clinically effective rapid- 
acting antidepressants is not any particular receptor or a 
subcellular target, but a more fundamental change in cortical 
activity (eg increased glutamate bursting and cortical exci-
tation), which leads to the activation of molecular pathways 
and synaptic function resulting in antidepressant effects 
through physiologically evoked changes in functional con-
nectivity, synaptic strength and synapse number.6 While it is 
tempting to connect these changes with mechanisms such as 
BDNF- TrkB signalling, the exact temporal gradients of these 
molecular changes have not been thoroughly investigated. 
However, as will be next discussed, studies with nitrous oxide 
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and flurothyl have given insights to the regulation of these 
signalling mechanisms.
2.2 | Rapid- acting antidepressants, 
slow electroencephalogram activity and 
TrkB signalling
The exceptional pharmacokinetics of nitrous oxide and fluro-
thyl make it possible to better differentiate acute pharmaco-
logical effects emerging during receptor engagement from 
those emerging immediately thereafter13 (Figure 2). To this 
end, we have conducted pharmaco- EEG studies and mo-
lecular analyses to show that during the ongoing blockade 
of NMDARs, that is during active gas flow and inhalation, 
nitrous oxide produces no regulation in the phosphoryla-
tion of TrkB, GSK3β and p70S6K.13 The regulation of these 
pathways only became regulated gradually once the gas flow 
was suspended. This period following the cessation of nitrous 
oxide flow was characterized by increases in the EEG delta 
(~1- 4  Hz) frequency power— a phenomenon also observed 
in human studies following nitrous oxide administration.27 
Similarly, these signalling pathways remained unregulated in 
samples collected immediately following a flurothyl- induced 
seizure (Rosenholm et al, unpublished), while strong phos-
phorylation of TrkB, GSK3β and p70S6K was present in 
brain samples collected 15 minutes later during the post- ictal 
period,13 another brain state which demonstrates prominent 
slow EEG activity. These studies suggest that the regulation 
of molecular pathways deemed important for antidepressant- 
like responses, such as activation of TrkB, to occur after 
the primary pharmacological effects of the treatments have 
subsided (Figure 2). Furthermore, these results may suggest 
that events related to synaptic plasticity and protein synthesis 
are differentially regulated during acute excitation evoked by 
the treatments versus the following adaptive state. However, 
studies with cellular resolution will be required to specifi-
cally localize the molecular changes.
The coinciding nature of slow EEG activity and TrkB 
signalling is also demonstrated by sedative drugs, which 
directly increase inhibition in the brain by different mech-
anisms.13 GABAergic volatile anaesthetics sevoflurane and 
isoflurane produce prominent TrkB phosphorylation.28 The 
effect of isoflurane on TrkB signalling is dose- dependent and 
most obvious changes are observed at dosing leading into 
deep anaesthesia.29 Moreover, the α2 noradrenergic agonist 
medetomidine— another hypnotic/sedative drug— readily 
activates TrkB receptors and increases slow- wave sleep 
like EEG activity.13 Surprisingly, we have also found high 
and sedative doses of ketamine, but not low subanaesthetic, 
to acutely induce TrkB signalling, again accompanied by 
increased slow EEG activity.14 Notably, the ability of sed-
ative doses of ketamine to increase TrkB signalling acutely 
appear independent of its HNK metabolite.14 However, to 
date, no thorough characterization which would feature 
multiple time- points of drug delivery has been made of the 
time- and dose- dependent effects of ketamine or other pu-
tative rapid- acting antidepressants on these pathways. Most 
importantly, while TrkB signalling and associated mecha-
nisms have been connected with rapid antidepressant ef-
fects, it remains unlikely— and against clinical knowledge 
and experience— that purely sedative drugs would work as 
antidepressants. Here, we speculate that while the sedative 
state may effectively trigger molecular pathways important 
F I G U R E  2  Molecular mechanisms regulated during and after nitrous oxide treatment in mice. A, During the acute effects of nitrous oxide 
EEG remains active, the phosphorylation of p44/42- MAPKT202/Y204 is up- regulated and the transcription of immediate- early genes (eg Bdnf) is 
increased, while phosphorylation of TrkBY816, p70S6kT421/S424 and the inhibitory Ser9 residue of GSK3β, remain unchanged. B, After nitrous 
oxide administration has ceased and the gas is eliminated from the brain, slow EEG activity becomes up- regulated along with increased TrkBY816, 
p70S6kT421/S424 and GSK3βS9 phosphorylation, while p44/42- MAPKT202/Y204 phosphorylation is decreased. Red arrows pointing upwards depict 
increased phosphorylation and blue arrows pointing downwards depict reduced phosphorylation
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for antidepressant effects, activation of these pathways may 
only be relevant in the context of the preceding treatment- 
induced cortical activation (ie a physiological driver of 
plasticity). This idea brings us to review this phenomenon 
from the perspective of sleep.
2.3 | Sleep and rapid- acting antidepressants
During physiological non- rapid eye movement (NREM) 
sleep, slow and synchronized cortical EEG activity be-
comes pronouncedly up- regulated during bouts of slow- 
wave sleep.8 Slow- wave sleep is generally thought to be 
important for facilitating or maintaining synaptic homeo-
stasis, learning and memory. Indeed, from the perspec-
tive of the brain, the 24- hour circadian cycle represents 
the interplay of a state of increased activity, which takes 
place throughout wake and is thought to induce synaptic 
potentiation for learning and memory, and reduced activity 
represented by the disconnection of the brain from the ex-
ternal environment during sleep. According to the influen-
tial synaptic homeostasis hypothesis (SHY),30 sleep is “the 
price the brain pays for plasticity.” Indeed, numerous stud-
ies have shown the connection of cortical activation, be it 
sleep deprivation, a motor coordination task or even local 
activation of brain networks by using transcranial magnetic 
stimulation, to the increased emergence of slow- wave ac-
tivity (SWA) during subsequent slow- wave sleep (SWS). 
Neuronal utilization during wake, as such, has been shown 
to be sufficient to up- regulate BDNF levels and induce re-
bound SWA in rodents.31 Within this context, we believe 
subanaesthetic ketamine, and related treatments, may rap-
idly incite cortical microcircuits resulting in increased syn-
aptic potentiation and strength.6,8 This is reflected in the 
increased amount of SWA which can be measured during 
subsequent sleep.
The SHY proposes that SWS may have an important 
function in maintaining functional synaptic homeostasis.30 A 
process entailing the renormalization of synaptic strength has 
been suggested to take place throughout deep sleep, where 
wake- up regulated levels of synaptic potentiation are re-
turned to preceding levels. Here, synapses that were most ac-
tive and potentiated during the day may preferentially remain 
protected from the renormalization and thus allow for rela-
tive changes in synaptic strength to be maintained. While the 
underlying mechanisms remain speculative, the main prin-
ciple is supported by ultrastructural and molecular studies, 
which show both the reduction of synapse size and synaptic 
AMPARs during sleep.32,33
The potential association of ketamine's effects with sleep 
homeostasis is strengthened by clinical findings, where ket-
amine was found to increase total sleep time, SWS and REM 
sleep in treatment- resistant depressed patients.34,35 Most 
importantly, the increases in the amount of SWA correlated 
with clinical improvement (ie antidepressant effects). These 
preliminary studies represent just a small fraction of the 
emerging studies connecting both sleep and circadian mech-
anisms to ketamine's antidepressant effects.8 With that being 
said, the study of ketamine in this context may prove to be 
particularly fruitful for understanding its complex interac-
tion with neurobiological mechanisms of sleep. Our recent 
effort in integrating some of the ideas of SHY to the study 
of rapid- acting antidepressants is known as the hypothesis of 
encoding, consolidation and renormalization in depression 
(ENCORE- D),6 a framework which discusses these themes 
beyond the scope of this review.
3 |  POTENTIAL SCIENTIFIC AND 
THERAPEUTIC IMPLICATIONS
As overviewed in the previous chapters, the effects of rapid- 
acting antidepressants can be divided into different tem-
poral phases based on the emerging electrophysiological, 
molecular and functional signatures. We hypothesize that 
these phases constitute mechanisms that work in conjunc-
tion to achieve alterations in neural network function which 
ultimately become visible as the amelioration of depressive 
symptoms.6 Agents that facilitate SWA directly without the 
preceding cortical excitation are likely not to function as 
rapid- acting antidepressants, despite the regulation of some 
of the molecular cascades implicated in synaptic plasticity 
and ketamine's antidepressant effects, such as activation of 
TrkB and inhibition of GSK3β. However, these mechanisms 
may be related to the emergence of antidepressant effects in 
the context of relevant neural activity and processes that may 
occur following cortical excitation and throughout sleep.6 It 
is important to highlight the notion that most, if not all, of the 
neurobiological mechanisms associated with ketamine's anti-
depressant effects are interconnected with physiological cir-
cadian rhythmicity and/or the sleep- wake cycle8 — a field of 
study which requires further attention. We will next discuss 
some of the potential scientific and therapeutic implications 
of the proposed mechanistic basis of ketamine and related 
rapid- acting antidepressants.
3.1 | Pharmacokinetics
One of the striking differences between ketamine and tra-
ditional antidepressant drugs is their pharmacokinetics. 
Ketamine is rapidly metabolized and is pharmacologically 
active for only a few hours (in rodents much less)— yet it 
produces a rapid amelioration of depressive symptoms that 
sustain long after the drug has been eliminated from the 
body. Whereas traditional antidepressants are administered 
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daily to eventually achieve steady- state concentrations, 
ketamine treatment focuses on giving a short infusion or a 
bolus dose. The antidepressant effects of ketamine begin to 
emerge immediately during the drug delivery and typically 
reach the peak effect after a night of sleep. What makes 
ketamine and agents such as nitrous oxide special maybe 
their relatively short duration of action, which is enough to 
induce cortical activity but also short enough not to perturb 
neuronal homeostasis (c.f. relapse after sleep deprivation, 
see Chapter 3.3). Here, drugs like MK- 801, phencyclidine 
(PCP) and memantine differ both in their actions towards 
NMDARs but also in their pharmacokinetics. For example, 
memantine, which has not demonstrated clear antidepressant 
effects in clinical trials,36,37 has a half- life of several days 
in human beings. The rapid properties of ketamine may ex-
plain the unique homeostatic adaptations it can trigger, and 
they encourage— somewhat counterintuitively— the search 
of novel rapid- acting antidepressant drugs with even shorter 
duration of pharmacological action. Similar potential may be 
held by psychedelic drugs with a rapid action, such as di-
methyltryptamine (DMT).38
3.2 | Dose and dosing matters
Ketamine is a good example of a drug whose effects 
greatly vary depending on the dose. Low subanaesthetic 
doses increase cortical excitability and glutamatergic neu-
rotransmission, whereas high anaesthetic doses suppress 
neural activity.15,39,40 As previously explained, low and 
high doses follow different dynamics in activating vari-
ous molecular pathways implicated in antidepressant re-
sponses. Surprisingly, it remains unknown whether high 
doses of ketamine also possess antidepressant efficacy. 
High doses may also have a window of pharmacological 
action when they primarily induce excitation, for exam-
ple when majority of the dose has been metabolized and 
the patient is again becoming responsive. Indeed, many 
anaesthetics display post- anaesthesia reactions known 
as emergence phenomena, where patients may show agi-
tation, confusion and hallucinations.41 Such reactions 
are also relatively common with volatile anaesthetics, 
which could similarly facilitate paradoxical excitation 
of the cortex during low drug concentrations.42 To our 
knowledge, no clinical trials have addressed whether su-
banaesthetic doses of volatile anaesthetics would possess 
antidepressant actions, although an interesting recent case 
report with sevoflurane indicate this.43 Notably, it may 
be that there is no optimal dosage that can be generalized 
to apply to every patient. Volatile and gaseous anaesthet-
ics, however, can be easily titrated almost in real time to 
a concentration or dosing that is most beneficial for the 
treatment, for example from the perspective of inducing 
optimal cortical activation and subsequent facilitation of 
slow- wave activity.
3.3 | Slow- wave sleep and consolidation of 
antidepressant effects?
The study rapid- acting antidepressants in the context of 
sleep may be one of the key aspects towards understanding 
the underlying neurobiological mechanisms. In this mini-
review, we have focused on hypotheses revolving around 
slow- wave sleep, but many other aspects and stages of 
sleep may turn out to be equally important. With that being 
said, slow- wave sleep presents an intriguing candidate for 
future studies to investigate in the context of rapid- acting 
antidepressant treatments. Experiments where slow- wave 
sleep is either disrupted or enhanced following ketamine 
treatment may provide important clues to the neurobio-
logical significance of sleep in general, as well as its role 
in the consolidation of antidepressant effects.6,8 In this 
context, it is important to note that sleep deprivation ef-
fectively and rapidly alleviates depression, but the depres-
sive symptoms often re- emerge after a subsequent sleep 
period or even a short nap. It is tempting to speculate that 
the fragility of the antidepressant effects of sleep depriva-
tion is associated with disruption of sleep physiology and 
thereby mechanisms allowing sustained antidepressant ef-
fects. Altogether, the disregard for sleep in both clinical 
and basic research may have more generally contributed to 
the soaring numbers of translational failures and hindered 
our ability to understand the core of ketamine's antidepres-
sant action.8,44
3.4 | Biomarker predicting rapid 
antidepressant efficacy
The post- ictal emergence of slow- wave EEG activity fol-
lowing ECT has been proposed to predict its efficacy 
and onset of antidepressant effects many decades ago45,46 
— long before the emergence of molecular signalling per-
spectives associated with antidepressant actions. Perhaps 
for this reason, the potential neurobiological significance of 
the EEG suppression has remained poorly studied in experi-
mental models. Our observations associate slow- wave EEG 
activity with the activation of the key molecular pathways 
implicated in rapid antidepressant effects and suggest there 
may be more to uncover in this association.6 Clinical stud-
ies demonstrating that subanaesthetic ketamine (and sleep 
deprivation) trigger homeostatic increases in slow- wave 
EEG activity further strengthens the association between 
slow- wave EEG, clinical responses and the neurobiology 
of sleep.
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Studies have reported several EEG (or MEG (magneto-
encephalogram)) findings to coincide with the emergence of 
ketamine's antidepressant effects. In psychiatric ECT, EEG is 
used to monitor seizure quality and the post- ictal emergence 
of slow EEG activity. Similarly, EEG could have potential in 
monitoring the cortical activation, and putative subsequent 
slowing, induced by ketamine and other potential rapid- acting 
antidepressant treatments. Our studies in rodents associate the 
emergence of slow EEG activity with the activation of mo-
lecular pathways important for synaptic plasticity, which sug-
gests that similar changes may also take place in the human 
brain under similar physiological conditions. However, further 
studies precisely characterizing the patterns of EEG activity 
and associated molecular changes are required. Moreover, un-
derstanding other physiological changes associated with the 
emergence of increased SWA or up- regulation of delta EEG 
power, such as changes in brain metabolism and glymphatic 
flow (that is increased during deep sleep and anaesthesia), 
may ultimately provide key information to understand the 
neurobiological significance of these phenomena.
3.5 | Circadian time of administration
The mechanisms overviewed in this review, such as the abil-
ity of rapid- acting antidepressants to provoke cortical exci-
tation and the subsequent emergence of slow EEG activity, 
suggest that the baseline brain state (ie level of excitability) 
of the underlying neural networks may ultimately determine 
outcomes of a treatment. Both homeostatic47 and circadian 
factors48 influence excitability, thus promoting the idea that 
the circadian time of drug or treatment administration may 
be relevant for the emergence of the therapeutic effects. For 
example, treatments administered early in the morning could 
produce different outcomes compared to those late in the 
evening.8 To this date, no studies have thoroughly addressed 
this question. The question is also of significant interest in 
terms of basic animal research, since most commonly used 
laboratory rodents are nocturnal (ie night- active).44 Although 
the contrast in their activity throughout vigilance states is not 
as clear as in human beings, there is a clear preference for 
sleep and rest during the light period, when most experiments 
(eg drug treatments, behavioural analyses and collection of 
samples for biochemical analyses) are conducted. Thus, ne-
glecting this issue may contribute to the problems in translat-
ing findings from basic research to the clinic.44
4 |  CONCLUSIONS
Activation of the BDNF receptor TrkB and its downstream 
signalling has been tightly connected with ketamine's an-
tidepressant effects. Despite an ever- increasing number of 
proposed mechanisms underlying ketamine- induced TrkB 
signalling and prospective targets and putative antidepressant 
drugs— mostly found using traditional depression models— 
few drugs have advanced further in the pipeline and none have 
come close to surpassing ketamine. We have taken another 
strategy by aiming to understand the effects of rapid- acting 
antidepressants by comparing the molecular and physiologi-
cal effects of drugs and treatments proven effective or shown 
promise in clinical studies including sleep deprivation, sei-
zures and nitrous oxide. Our observations indicate that these 
mechanistically diverse treatments share the ability of trigger-
ing prominent activation of cortical networks. Importantly, 
phosphorylation of TrkB and activation of its downstream 
signalling is largely unchanged during this initial excitation 
phase produced by the treatments and become only gradually 
regulated after the acute pharmacological/physiological ef-
fects have dissipated. Notably, the activation of TrkB signal-
ling appears to coincide with several characteristic features of 
deep sleep, most notably the facilitation of slow- wave EEG 
activity. While the mechanisms involved in the activation of 
these molecular signalling events remain unknown, we hy-
pothesize that treatments possessing rapid antidepressant po-
tential share the ability to up- regulate TrkB signalling during 
homeostatically evoked slow- wave sleep, and that this mecha-
nism may be associated with regulation of synaptic plastic-
ity during sleep. Here, future studies aimed at dissecting the 
temporal and spatial characteristics of rapid- acting antidepres-
sants effects throughout wake and sleep are warranted.
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